A peptide that controls the appetite at the level of the nervous system, could have a great potential for the development of future drugs to combat obesity. The PYY is secreted by the intestine according to the amount of calories that we are going to ingest, and it has a satiating action.

It has been observed that obese patients have lower fasting peptide concentrations than subjects with an adequate weight, and that these concentrations increase as weight loss occurs. Therefore, weight loss in obese subjects is associated with an increase in fasting PYY concentrations, as well as those who undergo surgery.

To verify this association, a group of healthy people was administered PYY, intravenously, to physiological doses, managing to reduce calorie intake by 30%. In addition, the duration of the meal and the subjective feeling of hunger also decreased, without any alteration in the gastric emptying being observed.

The World Health Organization (WHO) estimates that in 2015 around 2.3 billion adults will be overweight, and more than 700 million will be obese

Overweight and obesity have become a serious health problem, and not only in developed countries, as was previously thought. For various reasons, such as inadequate nutrition, excessive sedentary lifestyle, or poor nutritional education, chilling data have been reached regarding the number of people suffering from this type of disorder, which is increasing the incidence of cardiovascular diseases.

Leptin and the neural circuit regulation food intake and glucose metabolism (November 2019).